Board members

Time reveals the wisdom of bold decision-making in a changing market environment. We are due to reap the fruits of intelligent investments made during a challenging period. Investments in R&D, production and people demonstrate our commitment to the future.

Frederic Marguerre

Shareholders’ Representative President, Octapharma Plasma Inc. USA
Responsibility is not something you get, but something you take.

Wolfgang Marguerre

Chairman Octapharma Group
The return of octagam® to the market is an unequivocal indication of the solid scientific platform on which Octapharma operates. It is testimony to our resources, the quality of which inspire the trust of our stakeholders, clients and physicians.

Paulo Castro

Global Management Committee International Marketing

Tobias Marguerre

Managing Director Octapharma Nordic AB
Trust is not just a slogan, it is a way of life. Octapharma partners with health care providers and patients to provide them with every reason to trust in our products.

Flemming Nielsen

President Octapharma USA Inc.
With robust finances and smart decision-making Octapharma continues to make intelligent and well chosen investments into R&D and production, contributing to a positive outlook for the future.

Roger Mächler

Chief Financial Officer
The work of R&D today defines Octapharma products of tomorrow. Our scientists are dedicated to improving patients’ health by developing innovative medicines. Saving lives and improving quality of life is our daily source of motivation

Ulrich Thibaut

Research and Development
View Biography
To guarantee the quality and safety of all raw materials and final products is the prerequisite to comply with the expectation of our patients on the high standard of our products and to comply with the safety and quality requirements of our industry.

Josef Weinberger

Corporate Quality and Compliance Officer
2010 was a rather difficult year for the octagam production. However, through Octapharma's excellent team work, we managed to solve the technical root cause and succeeded in implementing a revised production process for octagam.

Gerold Rempeters

Corporate Production Officer